Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient

This article was originally published in The Pink Sheet Daily

Executive Summary

Clofarabine carries an average wholesale price of $2,812.50 per 20 mL vial, according to Medi-Span's Price Alert. Assuming no rebates, annual revenues for the product could be in the range of $45 mil.-$90 mil.

You may also be interested in...

Genzyme Clolar Approved For Pediatric Acute Lymphoblastic Leukemia

Indication follows advisory committee recommendation to approve clofarabine for ALL but not for pediatric acute myelogenous leukemia. Genzyme will have to redesign its confirmatory trial within two months.

Avastin, Erbitux Prices Invite Price Controls, Former NCI Deputy Says In Editorial

The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts